ArQule, Inc. (NASDAQ:ARQL) is an oncology-focused microcap biotechnology company. A graphical description of its pipeline shows six ongoing clinical trials studying five products. Its shares currently trade for under $2.20, after moving up and then down again in 2014, pursuant to depreciating through the past year and being removed from the NASDAQ Biotechnology Index (NASDAQ:IBB) on December 23rd.
ArQule has some cash on hand as well as investments. Though the company has obtained funds through partnerships, and might continue to in the future, it is not financially self-sustaining. Yet, there appear to be multiple ways for the experimental firm to reward investors. One reason is that it has a considerable amount of Net Operating Losses ("NOL")...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|